Abstracts tagged "Infection"

Abstract Number: 2817 • 2015 ACR/ARHP Annual Meeting
The Microbiome of Reactive Arthritis in a Guatemalan Cohort
Alexis Ogdie-Beatty¹, Carles Ubeda², Helga Raquel Garcia Ferrer³, Joan Von Feldt⁴, A Garcia Kutzbach⁵ and Jose U. Scher⁶, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Institute for Research in Public Health, Valencia, Spain, ³Society for Worldwide Med Exchange, North Bay Village, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, ⁶Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Reactive arthritis (ReA) is an inflammatory arthritis that typically follows infection. Several agents microbial agents have been implicated, particularly Shigella, Salmonella, Campylobacter in the…
Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Nan Bing¹, HuanYu Zhou¹, BaoHong Zhang¹, John D Bradley², Makoto Nagaoka³, Hernan Valdez⁴, Michael Vincent¹ and James D. Clark¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
Abstract Number: 2851 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Fabiola Atzeni¹, Marco Sebastiani², Valentina Panetta³, Fausto Salaffi⁴, Antonio Marchesoni⁵, Roberta Ramonda⁶, Florenzo Iannone⁷, Roberto Gorla⁸, Elisa Gremese⁹, Marcello Govoni¹⁰, Pier Carlo Sarzi-Puttini¹¹, Gianfranco Ferraccioli¹², Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ³L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁴Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁵Day Hospital of Rheumatology, G. Pini Orthopedic Institute, Chair of Rheumatology of Milan, Milan, Italy, ⁶Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ⁹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ¹⁰Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ¹¹Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ¹²Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: Infection is by far the most common and most important adverse effect of TNF inhibitors (TNFI) in the treatment of rheumatoid arthritis (RA) and…
Abstract Number: 674 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study
Hirofumi Nishikawa¹, Yoshinori Taniguchi¹, Takashi Karashima², Tetsushi Aita³, Susumu Nishiyama³, Yasuhiko Yoshinaga³, Yoshitaka Kumon⁴, Yoshiko Shimamura¹, Kosuke Inoue¹, Taro Horino¹, Taro Shuin² and Yoshio Terada¹, ¹Kochi University, Nankoku, Japan, ²Urology, Kochi University, Nankoku, Japan, ³Kurashiki Medical Center, Kurashiki, Japan, ⁴Chikamori Hospital, Kochi, Japan
Background/Purpose: Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA)…
Abstract Number: 2899 • 2015 ACR/ARHP Annual Meeting
Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France
laurent chiche¹, sarah malaekah², alexandre belot³, Brigitte Bader-Meunier⁴, gregoire rey⁵, Noémie Jourde-Chiche Sr.⁶ and mireille eb⁵, ¹internal medicine, Hopital Europeen, Marseille, France, ²pediatry, CHU Lyon, Lyon, France, ³Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵cepidc, paris, France, ⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Although regarded as a disease of adulthood, SLE is also seen in children, and is associated with an increased risk for aggressive clinical course…
Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting
Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians
Rebecca Sharim¹, Leny Mathew², Michael George³, Preethi Thomas⁴ and Misha Rosenbach⁵, ¹Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…
Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting
Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Seoyoung C. Kim⁶, Daniel H. Solomon⁷ and Karen H. Costenbader^8,9, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…
Abstract Number: 1343 • 2015 ACR/ARHP Annual Meeting
Mortality Due to Sepsis in Patients with Rheumatoid Arthritis
Orit Barrett¹, Ella Abramovich², Jacob Dreiher³, Victor Novack⁴ and Mahmoud Abu-Shakra⁵, ¹Department of Medicine D, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ²Department of Medicine D, Soroka University Medical Center and Ben-Gurion University, Beersheba, Israel, ³Clalit Health Services, Ben-Gurion University of the Negev, Beer Sheva,,, BeerSheba, Israel, ⁴Clinical Research Center, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ⁵Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Severe infections contribute significantly to the morbidity and mortality of patients with rheumatoid arthritis. The aim of the study was to identify the characteristics…
Abstract Number: 3193 • 2015 ACR/ARHP Annual Meeting
Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Jonathan Miner¹, Lindsey Cook¹, Raeann Shimak², Julie Fox¹, Alissa Young¹, Kristen Monte², Subhajit Poddar², Michael Diamond¹ and Deborah Lenschow¹, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that has infected more than 1 million individuals in the Western Hemisphere since 2014. …
Abstract Number: 1346 • 2015 ACR/ARHP Annual Meeting
The Presentation and Outcomes of Surgically Treated Septic Arthritis: the Impact of Culture Results
Ziv Paz¹, Mary Louise Fowler², Clara Zhu³, Sarah B. Lieber¹, Andrew Moore⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²School of Medicine, Boston University School of Medicine, Boston, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Clinically-suspected septic arthritis is culture-negative in 18-43% of cases. These patients are often treated surgically with associated morbidity, prolonged hospital stays and high medical…
Abstract Number: 3238 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection
Adrian Richter¹, Anja Strangfeld², Prof. Dr. Matthias Schneider³, Thomas Klopsch⁴, Andreas Kapelle⁵, Jörg Kaufmann⁶, Angela Zink⁷ and Joachim Listing⁸, ¹German Rheumatism Research Center, Berlin, Germany, ²Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁴Rheumatologist in private practice, Neubrandenburg, Germany, ⁵Rheumatologist, Hoyerswerda, Germany, ⁶Medical practice specialising, Ludwigsfelde, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Tumor-necrosis-factor-α inhibition (TNFi) was assumed to be a relevant mechanism for the treatment of sepsis[1]. However, randomized controlled trials failed to show a survival…
Abstract Number: 1349 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes of Septic Bursitis
Sarah B. Lieber¹, Clara Zhu², Mary Louise Fowler³, Andrew Moore⁴, Robert H. Shmerling⁵ and Ziv Paz¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medical School, Boston University School of Medicine, Boston, MA, ³School of Medicine, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Septic bursitis (SB) is a common condition that typically involves the olecranon and patellar bursae. It is unclear whether patients with SB treated surgically…
Abstract Number: 1357 • 2015 ACR/ARHP Annual Meeting
Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center
Yusuf Ziya Sener¹, Burak Yasin Aktas¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Ahmet Cagkan Inkaya³, Omer Karadag², Sule Apras Bilgen² and Sedat Kiraz², ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Infection Disease, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: CMV is a ubiquitous herpes virus associated with significant immunosuppression. Immunosuppressive treatments and ageing is well known risk factors for CMV reactivation. There are…
Abstract Number: 1450 • 2015 ACR/ARHP Annual Meeting
Clostridium Difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort
Daniel B. Horton^1,2,3, Brian L. Strom^1,3, Mary E. Putt³, Carlos D. Rose², David D. Sherry⁴ and Julia S. Sammons⁵, ¹Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Division of Pediatric Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, Infection Prevention and Control, Division of Infectious Diseases, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The incidence of Clostridium difficile infection (CDI) has increased among children, and CDI is associated with significant morbidity and mortality. Cases of C. difficile…
Abstract Number: 1521 • 2015 ACR/ARHP Annual Meeting
Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic
Renata Baronaite Hansen¹, Anne Brun Hesselvig², Rolf Magnus Arpi², Eva Kristin Jonassen¹, Gunhild Bukh¹ and Ole Rintek Madsen¹, ¹Department of Rheumatology/C, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Department of Clinical Microbiology, Department of Clinical Microbiology, Copenhagen University Hospital Herlev, Herlev, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) treated with biologic agents are at increased risk of infection. Therefore, screening for urinary tract infection (UTI) with urine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].